The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells

Genes and Cancer

Volumn 1, Issue 10, 2010, Pages 1044-1052

  Hollenhorst, Peter C ^a   Paul, Litty ^b   Ferris, Mary W ^a   Graves, Barbara J ^b  

^a Indiana University School of Medicine   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

ETS; ETV4; PC3; Prostate cancer; Transformation

Indexed keywords

PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ETV4; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CELL ASSAY; CELL GROWTH; CELL LINE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN PC3; CELL TRANSFORMATION; CONTROLLED STUDY; DEVELOPMENT; ENHANCER REGION; ETS GENE; GENE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MICROARRAY ANALYSIS; MUTATION; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION; WOUND HEALING;

EID: 79952846687     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910395578     Document Type: Article

References (37)

1. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2- ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15:4706-11.
2. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-8.
3. Hewett PW, Nishi K, Daft EL, Clifford Murray J. Selective expression of erg isoforms in human endothelial cells. Int J Biochem Cell Biol. 2001;33:347-55.
4. Hollenhorst PC, Jones DA, Graves BJ. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. 2004;32:5693-702.
5. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396-400.
6. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008;68:73-80.
7. Svensson MA, Lafargue CJ, Macdonald TY, et al. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest. Epub 2010 Oct 25.
8. Turner DP, Watson DK. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther. 2008;8:33-42.
9. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497-511.
10. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene. 2003;303:11-34.
11. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol. 2001;2:827-37.
12. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev. 2007;21:1882-94.
13. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448:595-9.
14. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2- ERG gene fusion in prostate cancer. Neoplasia. 2008;10:177-88.
15. Cai C, Hsieh CL, Omwancha J, et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol. 2007;21:1835-46.
16. Yochum GS, Cleland R, Goodman RH. A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Mol Cell Biol. 2008;28:7368-79.
17. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008;68:7629-37.
18. Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Two unique novel prostate-specific and androgenregulated fusion partners of ETV4 in prostate cancer. Cancer Res. 2008;68:3094-8.
19. Sementchenko VI, Schweinfest CW, Papas TS, Watson DK. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene. 1998;17:2883-8.
20. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A. 2009;106:12465-70.
21. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41:619-24.
22. Pergolizzi RG, Kreis W, Rottach C, Susin M, Broome JD. Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. Cancer Invest. 1993;11:25-32.
23. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998;58:2720-3.
24. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979;17:16-23.
25. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983;43:1809-18.
26. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis. 1997;18:1215-23.
27. Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009;138:245-56.
28. Sun C, Dobi A, Mohamed A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008;27:5348-53.
29. Liu HY, Zhou B, Wang L, et al. Association of E1AF mRNA expression with tumor progression and matrilysin in human rectal cancer. Oncology. 2007;73:384-8.
30. Hata H, Kitamura T, Higashino F, et al. Expression of E1AF, an ets-oncogene transcription factor, highly correlates with malignant phenotype of malignant melanoma through up-regulation of the membrane-type-1 matrix metalloproteinase gene. Oncol Rep. 2008;19:1093-8.
31. Nosho K, Yamamoto H, Adachi Y, Endo T, Hinoda Y, Imai K. Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis. Br J Cancer. 2005;92:1193-200.
32. Izumiyama Y, Ohiro Y, Higashino F, et al. E1AF expression is closely correlated with malignant phenotype of tongue squamous cell carcinoma through activation of MT1-MMP gene promoters. Oncol Rep. 2005;13:715-20.
33. Yamamoto H, Horiuchi S, Adachi Y, et al. Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. Carcinogenesis. 2004;25:325-32.
34. Hida K, Shindoh M, Yoshida K, et al. Expression of E1AF, an etsfamily transcription factor, is correlated with the invasive phenotype of oral squamous cell carcinoma. Oral Oncol. 1997;33:426-30.
35. Firlej V, Ladam F, Brysbaert G, et al. Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription. J Cell Sci. 2008;121:3393-402.
36. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell. 2003;114:241-53.
37. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell. 2002;1:393-401.